These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 16234765)

  • 1. [Deviation of activated partial thromboplastin time from optimal level after 12 hours of intravenous infusion of unfractionated heparin -- an independent predictor of recurrence and unfavorable 30-day prognosis in patients with myocardial infarction].
    Shalaev SV; Shava VP; Petrik ES; Pushnikova MA; Zhuravleva TD
    Kardiologiia; 2005; 45(10):27-30. PubMed ID: 16234765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
    French JK; Edmond JJ; Gao W; White HD; Eikelboom JW
    Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
    Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
    Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
    Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
    Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the aPTT and clinical events in acute coronary syndromes treated with unfractionated heparin.
    Mitrovska S; Jovanova S
    Bratisl Lek Listy; 2006; 107(11-12):422-5. PubMed ID: 17425158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
    Peters RJ; Spickler W; Théroux P; White H; Gibson M; Molhoek PG; Anderson HV; Weitz JI; Hirsh J; Weaver WD
    Am Heart J; 2001 Aug; 142(2):237-43. PubMed ID: 11479461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
    Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F
    Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time.
    Bozovich GE; Gurfinkel EP; Antman EM; McCabe CH; Mautner B
    Am Heart J; 2000 Oct; 140(4):637-42. PubMed ID: 11011339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.
    Granger CB; Hirsch J; Califf RM; Col J; White HD; Betriu A; Woodlief LH; Lee KL; Bovill EG; Simes RJ; Topol EJ
    Circulation; 1996 Mar; 93(5):870-8. PubMed ID: 8598077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
    Théroux P; Pérez-Villa F; Waters D; Lespérance J; Shabani F; Bonan R
    Circulation; 1995 Apr; 91(8):2132-9. PubMed ID: 7697841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.
    Bauer SR; Ou NN; Dreesman BJ; Armon JJ; Anderson JA; Cha SS; Oyen LJ
    Mayo Clin Proc; 2009 Dec; 84(12):1073-8. PubMed ID: 19955244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
    Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
    Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.
    Anand SS; Bates S; Ginsberg JS; Levine M; Buller H; Prins M; Haley S; Kearon C; Hirsh J; Gent M
    Arch Intern Med; 1999 Sep; 159(17):2029-32. PubMed ID: 10510988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
    Antman EM
    Circulation; 1996 Sep; 94(5):911-21. PubMed ID: 8790025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
    Lee MS; Wali AU; Menon V; Berkowitz SD; Thompson TD; Califf RM; Topol EJ; Granger CB; Hochman JS
    J Thromb Thrombolysis; 2002 Oct; 14(2):91-101. PubMed ID: 12714828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial.
    Lee LV
    Am J Cardiol; 1995 Jan; 75(1):7-13. PubMed ID: 7801868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.